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Introduction 66
Glucocorticoids have long been recognised to impact on cognitive function, especially with aging (1-67 3). Older individuals who exhibit learning and memory impairments have elevated glucocorticoid 68 levels that parallel both cognitive deficits and shrinkage of the hippocampus, a key locus for memory 69 formation. The hippocampus expresses a high density of corticosteroid receptors, both the lower 70 affinity glucocorticoid receptor (GR) and the higher affinity mineralocorticoid receptor (MR), and 71 these receptors are also abundant in other neocortical regions associated with cognition (4). Elevated 72 glucocorticoid concentrations in vitro and in vivo promote biochemical, electrophysiological and 73 structural changes in hippocampal neurons, which associate with poorer memory formation (5, 6). 74
Manipulations which maintain low glucocorticoid levels from birth (neonatal programming) or mid-75 life (adrenalectomy and low dose steroid replacement) prevent the emergence of cognitive deficits 76 with age (7). 77
Some patients with dementia, including those with Alzheimer's disease (AD), have elevated 78 circulating cortisol levels, which may contribute to AD pathogenesis (8, 9). It has been postulated that 79 excess glucocorticoids increase levels of amyloid precursor protein (APP) and APP cleaving enzyme 80 brain and white adipose tissues were collected and snap frozen on dry ice. Frozen tissue (50-80mg) 117 was homogenized in 700μl of chilled Krebs Buffer and a cleared homogenate prepared by 118 centrifugation at 3500rpm for 5 minutes. The protein concentration of this homogenate was 119 determined by Bradford assay. For the assay, 25μl of 10mM NADPH was added to 250μg of the 120 homogenate in a final volume of 200μl chilled Krebs buffer and incubated at 37°C for 20 minutes. 121 3H-cortisone (25μl of 200nM) was then added and the assay incubated for a further 15 minutes prior 122 to termination by rapid freezing on dry ice. was determined by measuring the conversion of 3 H-cortisone to 3 H-cortisol relative to that in tissue 126 from vehicle treated mice. 127
Animals 128

All in vivo experiments were performed under a project license issued under the UK Scientific 129
Procedures (Animals) Act, 1986, and with local ethical committee approval. Male C57Bl/6 mice were 130 obtained from Harlan (UK). Male mice were chosen to eliminate the potential effects of gonadal 131 hormonal fluctuations observed in females. Animals were group-housed under controlled lighting (on 132 07.00-19.00h) and temperature (22°C), with access to food and water ad libitum. Experimental 133 procedures are summarised in Table 1 . 134
For measurement of pharmacodynamic inhibition following oral administration, oral gavages with 135 vehicle (38% PEG, 2% DMSO, 60% saline; Sigma, Poole, UK) or UE2316 dissolved in vehicle were 136 performed in the morning in animals aged 8-10 weeks (n=3 per dose). Animals were sacrificed post 137 dosing (1, 4 and 6 hours) and the tissues retained for analysis of 11β-HSD1 inhibition. 138
For assessment of pharmacodynamic inhibition following subcutaneous administration, C57Bl/6 mice 139 (8-10 months, Harlan UK) (n=3 per group) were treated with either vehicle (50:50 DMSO: PEG, 140
Sigma) or 10mg/kg/day UE2316 in vehicle via subcutaneously implanted Alzet osmotic minipumps(model 2004, Charles River, Margate, UK) for 14 days. Animals were sacrificed at this stage and the 142 tissues retained for analysis of 11β-HSD1 inhibition. 143
To show that the effects of UE2316 were not merely due to any peripheral metabolic actions of 11β-144 HSD1 inhibition, the agent was administered intracerebroventricularly to aged male C57Bl/6 mice (24 145 months, obtained from an in-house stock) were treated with either vehicle (artificial CSF; Alzet; 146 Charles River) (n=9) or 100ng/h UE2316 in artificial CSF (n=8) administered via 147 intracerebroventricular (icv) infusion, for 9 days, as previously described (23). 148
For assessment of the effects of UE2316 on cognition in aging animals, aged male C57Bl/6 mice (22 149 months, Harlan UK) were treated with either vehicle (n=6), 5mg/kg/day UE2316 (n=8) or 150 Food intake and body weight were monitored weekly throughout. For the long term study in which 160 UE2316 was administered by incorporation in the diet, 6-7 month old Tg2576 male mice that were 161 screened for eye color, coat color and rd1 homozygosity for the Pde6b rd1 retinal degeneration 162 mutation by Taconic were fed with control diet (RM1) (n=16) or with RM1 containing 175 ppm 163 UE2316 (for a calculated dosage of 30 mg/kg/day) (n= 32) (Special Diet Services, Broxburn, UK) for 164 up to 57 weeks. Food intake and body weights were monitored weekly throughout the experiment and 165 drug dosages were calculated based on average daily food intake. Each cohort of mice underwent 166 repeated longitudinal cognitive testing.
Behavior 168
Mice were acclimatized to the behavior room for at least one hour before all procedures in order to 169 minimize stress. All behavioral testing was conducted during the day between 9am and 12pm. 170
Memory in passive avoidance 171
Passive avoidance was assessed over 2 days (for aging studies in C57Bl/6 mice on days 13 and 14 172 after the start of treatment, for the short term UE2316 study in Tg2576 mice on days 27 and 28 and at 173 weeks 15 and 41 in the long term UE2316 Tg2576 study) in a step through light/dark box passive 174 avoidance apparatus (Ugo Basile Comerio, VA, Italy) (13). On the first day, the latency to enter the 175 dark compartment from the light compartment was measured, with the door to the dark compartment 176 opening 30 seconds after the start of the trial. Twenty four hours later, the latency to enter the dark 177 compartment was repeated, which was followed by a mild 0.3mA, 2 second foot-shock in the dark 178 compartment. The mice were then retested 6 hours later for the latency to enter the dark compartment, 179 this time without a foot-shock. The latencies were measured automatically by the device following the 180 opening of the door separating the light and dark compartments with a maximal time allowed of 300 181 seconds. Mice that did not enter the dark compartment were eliminated from analysis. 182
Y maze 183
Y maze testing of spatial hippocampal memory was performed as previously described with a 2 hour 184 inter-trial interval (ITI) on day 10 following the start of treatment in the aged UE2316 study (15). For 185 the UE2316 icv administration study, Y maze testing was performed on day 8 of treatment. The 186 amount of time spent in each arm was measured and analyzed using AnyMaze software (Stoelting, 187
Dublin, Ireland). 188
Open field 189
The open field test was performed on day 23 of the short term Tg2576 study and week 38 of the long 
Morris water maze 206
Morris water maze testing was performed as previously described on day 14 of the short term study 207 and week 52 of the long term study (24). For the short term treatment study in Tg2576 mice, mice 208 who did not swim (i.e. did not engage with the task) during the visible platform test, in which a visual 209 cue (i.e. stacked Lego blocks) was placed on the submerged platform in the tank and no visuospatial 210 clues were present (curtains were closed) were eliminated from analysis. The mice undertook 4 trials 211 per day with a 20 minute inter trial interval and a maximum swim time of 90 seconds per trial for 4 212 days. Latency, swim speed and the percentage of time spent in each quadrant of the pool were 213 measured by Watermaze software (Actimetrics, Evanston, IL, USA). In the long term treatment study, 214 mice were initially assessed after 12 months of treatment for their ability to engage in the visible 215 platform test. In this instance, mice that were able to find the platform and improve their latencies 216 after 2 days of 4 x 90 second trials were then tested in the spatial water maze, in which the platform 217 remained submerged without a visual cue on top and the mice utilised spatial clues located around themaze (curtains open). Mice were tested in 4 x 90 second trials per day over 6 days. Twenty four 219 hours after the final spatial water maze trial, the mice were then tested in the 90 second probe test, in 220 which the hidden platform was removed from the tank and the percentage of time spent swimming in 221 the target quadrant was measured. 222
After behavioural testing, mice were sacrificed by cervical dislocation on day 29 of vehicle or 223 UE2316 treatment in the short term study or after 44 and 57 weeks in the long term study. The brains 224 were removed and hemisected coronally. One half of the brain was dissected and cortex, hippocampus 225 and cerebellum were immediately frozen on dry ice and stored at -80°C for further analysis. The other 226 half was fixed in 4% paraformaldehyde in PBS (4% PFA) (VWR, Lutterworth, UK) and 227 cryoprotected in 30% sucrose (Sigma) overnight at 4°C before storage at -80°C for 228
immunohistochemistry. 229
Immunohistochemistry 230
All immunohistochemistry was performed on free floating 25 µm sections stored at -20°C in 231 cryoprotectant (50 mM phosphate buffer, 25% glycerol, 25% ethylene glycol, Sigma). Sections were 232 transferred to a 12 well tissue culture plate with Netwell inserts (VWR) and washed in PBS. Antigen 233 retrieval was performed by heating the sections in sodium citrate buffer, pH 6.0 (Sigma) at 95°C for 234 15 minutes, followed by peroxidase treatment (1% H 2 O 2 in PBS; Sigma) for 30 minutes to remove 235 endogenous peroxidase activity, washed and then blocked with the appropriate serum for 1 hour 236 followed by overnight incubation at 4°C with the antibody of choice. For staining using the 6E10 237 antibody for visualization of amyloid beta plaques, the sections were blocked using the mouse on 238 mouse (MOM) Ig blocking reagent (Vector Laboratories, Peterborough, UK) followed by overnight 239 incubation with a 1:1000 dilution of beta amyloid 1-16 mouse monoclonal antibody (6E10) (Covance, 240
Cambridge Bioscience, Cambridge, UK). Following washing, sections were incubated with secondary 241 antibody for 1 hour at room temperature. Staining was visualised using the Vectastain ABC kit and 242
DAB peroxidase substrate kit (Vector Laboratories). The sections were then mounted on Superfrost 243
Plus slides (VWR), dehydrated and coverslipped. The number of 6E10 positive plaques per brain areawas counted by an experimenter blinded to the treatment group using a Zeiss Axioskop and the 245 KS300 imaging program (Zeiss, Eching, Germany). Plaque area, measured using the same program, 246 was expressed as plaque area divided by the total area of the brain region. Iba-1 antibody was 247 purchased from Abcam (Cambridge, UK). Goat and rabbit serum were purchased from Sigma. 248
Biotinylated rabbit anti-goat IgG antibody and biotinylated rabbit anti-sheep IgG antibody were 249 purchased from Vector Labs. 250
Western blotting 251
Protein extracts were prepared from brain areas by homogenization in Krebs buffer containing 252 protease inhibitor (Roche, Burgess Hill, UK) followed by centrifugation at 3000 RPM for 5 minutes. 253
Protein concentration of the supernatant was measured using the Bradford Assay (BioRad, Hemel 254
Hempstead, UK). Proteins were separated by SDS-PAGE using NuPAGE Novex 4-12% bis-tris gels 255 (Invitrogen, Paisley, UK) and transferred to nitrocellulose membranes (0.2µm pore size; Invitrogen). 256
Membranes were blocked for 1 hour at room temperature in 5% non-fat dry milk blotting grade 257 
Results
272
UE2316 inhibits 11β-HSD1 in the brain 273
We previously reported the discovery and pharmacological effects of the selective 11β-HSD1 274 inhibitor UE1961, which was based on a thiophene amide scaffold (15). However, this molecule has 275 sub-optimal potency and pharmacokinetic properties for progression to late-stage preclinical 276 development. Further medicinal chemistry optimisation of this compound, replacing the 277 decahydroquinoline and substituted piperidine groups flanking the thiophene core, led to the 278 identification of UE2316 ( Figure 1A ). UE2316 displays greater potency than UE1961, excellent 279 selectivity and an improved drug metabolism and pharmacokinetic profile for use in in vivo studies 280 results from these studies were in agreement with those from previous studies (19, 20) . UE2316 was 286 thus chosen to investigate the effects of chronic 11β-HSD1 inhibition on cognitive impairment and 287 AD pathology in mouse models using either SC or oral administration. 288
UE2316 acts in the brain to improve cognition in aged wild type mice 289
To assess the effects of UE2316 on memory in cognitively impaired mice, C57BL/6 male mice aged 290 22 months were randomly assigned to treatment with 0, 5 or 15 mg/kg/day of UE2316 via SC 291
implanted Alzet minipumps for 14 days. In the Y-maze, a non-stressful test of hippocampal-292 associated spatial memory, there was a significant increase in time spent exploring the novel arm after 293 a 120 min inter-trial interval in mice receiving 15 mg/kg/day UE2316 compared to vehicle-treated 294 controls (Figure 2A) . Cognition was also assessed in the passive avoidance task, which tests 295 emotional and fear associated memories (13). During the retention phase of the passive avoidance 296 test, UE2316 increased latency to enter the dark compartment at both5 and 15 mg/kg/day compared 297 with vehicle-treated mice, indicating improved memory (of the footshock) ( Figure 2B) . 298
To investigate whether brain-specific inhibition of 11β-HSD1 was responsible for these improvements 299 in cognition, we delivered UE2316 directly to the brain of aged (24 month old) C57BL/6 mice at an 300 appropriate concentration via icv administration for 9 days. Post-mortem analysis of whole brain 301 samples revealed 39.9 ± 5.5 % inhibition of 11β-HSD1 was achieved with a 100 ng/h infusion. 302
Vehicle-treated aged controls showed impaired spatial memory in the Y maze (similar times spent in 303 all 3 arms) as previously reported (15). Mice treated with icv UE2316 spent more time exploring the 304 novel arm of the Y-maze than vehicle-treated mice, indicating an improvement in spatial memory 305 after 8 days of treatment ( Figure 2C) . 306
UE2316 improves cognition in a murine model of Alzheimer's disease 307
Following confirmation of the effects of 11β-HSD1 inhibition using UE2316 in age-related cognitive 308 impairment, we examined effects of short-term UE2316 administration in the Tg2576 mouse model of 309 AD. Tg2576 mice carry a transgene with mutations at amino acids 670 and 671 in the human APP 310 gene under the control of the hamster prion promoter, which leads to accumulation of Aβ plaques in 311 the brain from 9-12 months of age with consequent cognitive impairment (25). Singly housed age-312 matched male mice were separated into 4 groups of 10 mice per group: wild type or Tg2576 mice 313 administered vehicle or UE2316. Mice were treated by 2 SC implanted Alzet minipumps from 14 314 months of age for 29 days. No treatment-related adverse effects on final body weight, daily food 315 intake or adrenal size were observed. However, as previously reported, Tg2576 mice weighed less 316 than their wild type littermates throughout the study despite consuming more food (Supplementary 317 Figure 1A -B) , which may reflect their increase in locomotor activity and hypothalamic dysfunction 318 (26,27).Tg2576 mice perform poorly in the Y-maze spatial memory test due to retinal degeneration, therefore, 320 fear-associated memory was assessed in the passive avoidance task, which is not dependent on visual 321 acuity. In this test, performed on days 27 and 28 of drug or vehicle administration, UE2316 treatment 322 increased latencies in re-entry to the dark compartment at 6 hours post footshock in both control and 323 Tg2576 mice ( Figure 3A) , suggesting an improvement in fear associated memory with drug treatment. 324
The effect of UE2316 treatment was particularly pronounced in Tg2576 mice, which may reflect a 325 difference in sensitivity to the electrical shock in this mouse strain. In a separate open field test, no 326 difference was observed in the time spent in the inner zone in either wild type or Tg2576 mice with or 327 without drug (two way ANOVA, treatment effect: p=0.98), suggesting that UE2316 does not affect 328 anxiety ( Figure 3B) . No difference in speed was observed between either strain, in the presence or 329 absence of drug (two way ANOVA, treatment effect: p=0.94, data not shown). 330
In spontaneous alternation, a test of working hippocampal memory, Tg2576 mice tended to enter 331 more arms than the control mice (p=0.06), which again may be due to their increased locomotion 332 (data not shown) (26). Treatment with UE2316 led to a trend in increased percentage alternation in 333 both wild type and Tg2576 mice compared to vehicle (two way ANOVA, treatment effect: p=0.06) 334 ( Figure 3C) . 335
UE2316 prevents cognitive decline in a murine model of Alzheimer's disease 336
Effects of long-term UE2316 treatment were examined by administering UE2316 in the diet to 6-7 337 month old Tg2576 mice over a period of 57 weeks. The mice on the UE2316-supplemented diet 338 maintained an average daily dose of approximately 30 mg/kg/day throughout the experiment and did 339 not exhibit any adverse effects (Supplementary Figure 2A) . UE2316-treated mice tended to weigh less 340 than vehicle-treated mice up to 44 weeks (ANOVA, p<0.01) despite eating more food (ANOVA, 341 p<0.001) (Supplementary Figure 2B-C) . In contrast to the short-term study, mice were pre-screened 342 for retinal degeneration (RD) and only those which were RD negative were included. Memory was 343 assessed at intervals using passive avoidance, spontaneous alternation and Morris Water Maze tests.
Fear associated memory was assessed using the passive avoidance test after 15 and 41 weeks of 345 treatment. As expected, at 15 weeks, when mice were aged 10-11 months, similarly increased 346 latencies were observed following training in both the vehicle and UE2316-treated groups, consistent 347 with preserved cognitive function at this age ( Figure 4A ). In contrast, after 41 weeks of treatment, 348 when the mice were aged 16-17 months, vehicle-treated mice exhibited cognitive impairment as 349 demonstrated by lack of prolongation of latency after training, but Tg2576 mice treated with UE2316 350 maintained an increase in latency to enter the dark compartment 6 hours post shock, indicating that 351 UE2316 prevents an age-associated decline in fear associated memory ( Figure 4B anxious compared to wild type mice (two way ANOVA, genotype effect: p<0.01) ( Figure 5A ). There 356 was also an increase in locomotion in Tg2576 mice when compared to wild type mice (two way 357 ANOVA, genotype effect: p<0.01), but no effect of treatment (two way ANOVA, treatment effect: 358
p=0.69). 359
Working memory was assessed at 39 weeks of treatment using the spontaneous alternation test. 360
UE2316 increased spontaneous alternation (
Figure 5B), although there was no difference in the total 361 number of arm entries (data not shown). 362
Spatial memory was assessed in the Morris Water Maze after 52 weeks of treatment (mice aged 18-19 363 months). Swim speeds were not affected by UE2316 treatment and there was no difference between 364 strains (data not shown). UE2316 reduced the time taken to find the hidden platform across the testing 365 period ( Figure 5C ), and increased time spent in the target quadrant during the probe test performed 24 366 hours after the final trial (vehicle: 34.2±3.2%, UE2316: 52.1±5.1%, p=0.02), consistent with 367 improved spatial learning and retention (Supplementary Figure 3A) . 368
Effect of UE2316 on Aβ plaques in the brain
Immunohistochemistry with 6E10 antibody (28), which detects Aβ1-16, was performed on Tg2576 370 brains to determine whether UE2316 affected the number and volume of Aβ plaques (wild type 371 control brains were not analysed as these mice do not develop amyloid plaques) ( Figure 7A) . 372
Short-term 4-week UE2316 treatment decreased Aβ plaque number in the cortex and amygdala but 373 not the hippocampus of 15m old Tg2576 mice ( Figure 6A ). The total plaque number in the brains of 374 Tg2576 mice was 54% lower in UE2316-treated than vehicle-treated mice. Plaque areas were 375 correspondingly reduced ( Figure 6B) . 376
After chronic 44-week treatment with UE2316 (mice aged 17-18 months) there were a similar number 377 of Aβ plaques in the cortex and hippocampus as in mice treated with UE2316 for only 4 weeks 378 ( Figure 6C ). However, there were fewer Aβ plaques in the brains of the vehicle-treated group from 379 the 44-week study than in the vehicle-treated animals from the 4-week study. In the 44-week study 380 there was no significant effect of UE2316 on number of Aβ plaques. 381
To explore possible mechanisms mediating the effects of short-term UE2316 treatment on Aβ plaque 382 burden in the cortex we conducted western blot analyses of selected proteins involved in Aβ 383 generation and metabolism, the expression of which are known to be regulated by glucocorticoids 384 ( Figure 7B ). UE2316 treatment did not modulate BACE protein expression in either WT or Tg2576 385 mice (Table 2) . Nor did UE2316 alter ADAM10, a metalloproteinase possessing α-secretase activity 386 involved in the non-amyloidogenic pathway of APP processing (29) ( Table 2) . However, UE2316 387 significantly increased, by 31% and 34% respectively, insulin degrading enzyme (IDE) protein 388 expression in the cortex of both control and Tg2576 mice (Table 2) . No difference in IDE expression 389 was found in the brains from mice treated with UE2316 for 44 weeks (IDE to beta-tubulin ratio: 390 vehicle: 0.016 + 0.004 vs UE2316: 0.011 + 0.002; Student's t-test, p=0.22). 391 PSD95 and synaptophysin, markers of synaptic density (30,31), were unaffected by UE2316 (Table  392 2). In addition, microglial density was not increased as evidenced by no change in Iba1 levels (32) 393 (Table 2) . CD31 staining was also conducted to probe for potential changes in cerebral vascular 394 density, as 11β-HSD1 null mice exhibit enhanced angiogenesis (33) , but no effect of UE2316 was 395 observed (Table 2) . 396
397
Discussion
398
We have generated UE2316, which is a potent and selective inhibitor of 11β-HSD1 in mouse brain. 399 UE2316 administered either systemically or directly to the brain induces improvements in memory in 400 cognitively impaired rodents. In aging mice the effects of UE2316 recapitulate those of other selective 401 11β-HSD1 inhibitors (15, 16) and provide further evidence that short term inhibition of 11β-HSD1 in 402 the brain improves memory impairments associated with aging. Moreover, our data demonstrate that 403 these improvements are associated with inhibition of 11β-HSD1 specifically in the brain since mice 404 treated with icv administration with sub-systemic doses display memory improvements comparable to 405 those observed in mice treated systemically. The effects are evident across a range of behavioral tasks 406 that involve the hippocampus, in contrast with the attenuation of contextual fear-associated memory 407 that we previously reported with UE2316 which is likely mediated in different brain regions (19). It is 408 likely that these short term improvements in memory are due to the effects of reduced intracellular 409 corticosterone in regions of the brain such as the hippocampus, which are sufficient to reverse the 410 memory-impairing effects of glucocorticoids in aged mice (17). Structural changes to the 411 hippocampus, such as synaptic and dendritic atrophy may be reversed by reduced intracellular 412 glucocorticoid levels over a period of hours and weeks respectively, and could be responsible for the 413 short term memory improvements observed in these studies (34,35). However, we also observed 414 significant improvements in memory with long term 11β-HSD1 inhibition which may be mediated by 415 structural hippocampal changes. It should be noted that behavioral testing was only carried out in 416 male mice and the exploration of any potentially sexually dimorphic effects of 11β-HSD1 inhibition 417 will require separate, comparative studies in male and female mice. 418
There is now substantial evidence from studies in rodents and in humans that reductions in 11β-HSD1 419 activity in the brain provides beneficial effects on the cognitive decline associated with aging (15, 16, 420 18, 23). However, to date no studies have been published that assess the effects on 11β-HSD1 421 inhibition in rodent models of AD. We found that short term (29 days) treatment of already 422 cognitively-impaired 14-month old Tg2576 mice with UE2316 led to improvements in memory 423 during the passive avoidance task. UE2316 also improved latency in wild type mice but to a lesser 424 extent than in Tg2576 mice. Our data also demonstrate that long term inhibition of 11β-HSD1 in 425 Tg2576 mice maintains cognitive performance with aging since age-matched mice without UE2316 426 treatment are cognitively impaired in tests performed from 16 months of age onwards. Moreover, 427 cognitive improvement with 11β-HSD1 inhibition is maintained in the presence of significant 428
Alzheimer's pathology. 429
In the Tg2576 mouse strain, Aβ plaques have been shown to develop from 9 months of age onwards, 430 associated with impairments in cognitive ability in memory tests from 10-12 months (25). As 431 expected, when we examined the brains of the Tg2576 mice Aβ plaques were observed in the cortex, 432 amygdala and hippocampus. Short term UE2316 treatment substantially decreased Aβ plaque number 433 and area in the cortex and amygdala of Tg2576 mice. In contrast, in a separate cohort of mice from 434 which those with retinal impairment were excluded, we observed less Aβ plaque burden and no 435 statistically significant effects of chronic UE2316 administration. This likely reflects the differences 436 in animals with and without visual impairment. Overall, the results suggest that treatment with 437 UE2316 has a disease-modifying effect on amyloid plaque deposition in Tg2576 mouse brains by 438 impairing plaque accumulation. However, our findings dissociate cognitive improvement from Aβ 439 plaque pathology after chronic treatment, suggesting the mechanism of improved cognition with 11β-440 HSD1 inhibition is not mediated solely through reduced plaque burden. Whatever the mechanism, the 441 effect on cognition is likely associated with lowered intracellular glucocorticoid levels in the brain, 442 and the consequent altered balance of glucocorticoid and mineralocorticoid receptor action (23). 443
Additionally, we observed an increase in cortical IDE protein levels with short term UE2316 444 treatment. This increase may explain, in some part, the reduction in plaque numbers and plaque area 445 in the drug-treated mice, as previous studies have demonstrated that overexpression of IDE or 446 neprilysin in the neurons of transgenic mice significantly reduced brain amyloid beta levels andslowed or completely prevented amyloid plaque formation in APP TG mice (36), while IDE null mice 448 have excess cerebral accumulation of Aβ (37). In humans, genome-wide association studies report a 449 higher susceptibility to AD in Finnish patients with polymorphisms of IDE, suggesting that the rate of 450 Aβ degradation may be an important factor in the development of human AD (38). However, the lack 451 of IDE induction with chronic UE2316 administration, in the face of persisting benefits for cognitive 452 function, suggests that other pathways are involved in cognitive protection with 11β-HSD1 inhibition. 453
Alternatively, Tg2576 mice selected for intact vision may be relatively resistant to glucocorticoid 454 effects on IDE and Aβ turnover. 455
These pre-clinical results support the concept that 11β-HSD1 inhibition may be efficacious for 456 memory impairments not only with aging, but also in AD. A recent phase 2 clinical trial in patients 457 with mild-moderate AD was halted, however, when the selective 11β-HSD1 inhibitor ABT-384 failed 458 to show non-inferiority against donepezil for the primary endpoint of ADAS-Cog score (39). 459
Although a pharmacodynamic study of ABT-384 using stable isotope d4-cortisol tracer has been 460 reported (40), it remains uncertain whether ABT-384 inhibited 11β-HSD1 adequately in brain since: 461 data were presented for only two control subjects without administration of ABT-384; after ABT-384 462 administration, d3-cortisol levels (generated by 11β-HSD1) (41) were very low in plasma, consistent 463 with systemic enzyme inhibition, and this may account for the undetectable levels of d3-cortisol in 464 CSF; and the maximum CSF concentrations of ABT-384 achieved, which were present for only a 465 short time after dosing, were not high enough to inhibit 11β-HSD1 by more than 10%, according to 466 published potency of the compound. The benefits of 11β-HSD1 inhibition may only be apparent in the 467 treatment of early disease, when the combination of symptomatic cognitive improvement and 468 potential for disease modification we have observed in the mouse model of AD may be most useful. 
